Cell Source Asset Growth

What does Cell Source do? Cell Source, Inc. generates revenue through the development and commercialization of its Veto Cell immune system management technology, which selectively blocks immune responses in allogeneic hematopoietic stem cell transplantation (HSCT). The company's lead product, Veto Cell technology, is in pre-clinical phase and targets haploidentical stem cell transplants under mild conditioning regimens. Its product pipeline includes VETO CAR-T therapies for B-cell malignancies and solid tumors, as well as Veto Cell applications for kidney and liver transplants and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary, Cell Source Limited (CSL), supports these initiatives. Cell Source, Inc. focuses on developing immune tolerance biotechnology for clinical applications, targeting healthcare providers and transplant centers that require solutions for immune response management. The company's Veto Cell technology aims to enable safer and more effective allogeneic HSCT procedures, particularly for patients needing haploidentical transplants. The firm's pipeline products, including VETO CAR-T and Veto Cell kidney and liver transplants, are designed to address unmet needs in oncology and organ transplantation markets. The company's revenue model relies on the future commercialization of its proprietary technologies, with Veto Cell technology as the cornerstone. Its pre-clinical stage products, such as VETO CAR-T for B-cell malignancies and Veto Cell liver transplants, are positioned to enter clinical trials and eventually reach the market. Cell Source Limited (CSL) operates as a wholly owned subsidiary to advance these therapeutic approaches within the cell therapy sector. Cell Source is one of the most popular companies on Eulerpool.